Tags

Type your tag names separated by a space and hit enter

[Leu-enkephalin homogeneously labeled with tritium in studying the Selank inhibiting effect on the enkephalin-degrading enzymes of human plasma].
Bioorg Khim. 2004 May-Jun; 30(3):234-40.BK

Abstract

A method of analysis of enkephalinase activity in blood plasma based on the application of Leu-enkephalin generally labeled with tritium at all its amino acid residues was developed. The method allows the simultaneous estimation of activity of several peptidases in microquantities of tissues. [G-3H]Leu-enkephalin was prepared by the method of solid phase catalytic isotope exchange (120 Ci/mmol) and subjected to proteolysis by the treatment with blood plasma. The resulting radioactive metabolites were separated by HPLC in the presence of the mixture of unlabeled fragments of Leu-enkephalin as internal standards. It was shown that aminopeptidases, dipeptidylaminopeptidases, and dipeptidylcarboxypeptidases respond for approximately 80%, 2%, and 10% of the total enzymatic activity, respectively. The new pathway of degradation of Leu-enkephalin by carboxypeptidase that provides for approximately 6% of the total enkephalin-degrading activity was discovered. Bestatin was shown to predominantly inhibit aminopeptidases and carboxypeptidases, whereas Selank is more specific for carboxypeptidases and dicarboxypeptidases. The English version of the paper: Russian Journal of Bioorganic Chemistry, 2004, vol. 30, no. 3; see also http://www.maik.ru.

Authors

Zolotarev IuA
No affiliation info available
Sokolov OIu
No affiliation info available
Kost NV
No affiliation info available
Vas'kovskiĭ BV
No affiliation info available
Miasoedov NF
No affiliation info available
Zozulia AA
No affiliation info available

MeSH

AminopeptidasesEnkephalin, LeucineExopeptidasesHumansLeucineOligopeptidesProtease InhibitorsTritium

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

rus

PubMed ID

15344652

Citation

Zolotarev, Iu A., et al. "[Leu-enkephalin Homogeneously Labeled With Tritium in Studying the Selank Inhibiting Effect On the Enkephalin-degrading Enzymes of Human Plasma]." Bioorganicheskaia Khimiia, vol. 30, no. 3, 2004, pp. 234-40.
Zolotarev IuA, Sokolov OIu, Kost NV, et al. [Leu-enkephalin homogeneously labeled with tritium in studying the Selank inhibiting effect on the enkephalin-degrading enzymes of human plasma]. Bioorg Khim. 2004;30(3):234-40.
Zolotarev, I. u. A., Sokolov, O. I. u., Kost, N. V., Vas'kovskiĭ, B. V., Miasoedov, N. F., & Zozulia, A. A. (2004). [Leu-enkephalin homogeneously labeled with tritium in studying the Selank inhibiting effect on the enkephalin-degrading enzymes of human plasma]. Bioorganicheskaia Khimiia, 30(3), 234-40.
Zolotarev IuA, et al. [Leu-enkephalin Homogeneously Labeled With Tritium in Studying the Selank Inhibiting Effect On the Enkephalin-degrading Enzymes of Human Plasma]. Bioorg Khim. 2004 May-Jun;30(3):234-40. PubMed PMID: 15344652.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [Leu-enkephalin homogeneously labeled with tritium in studying the Selank inhibiting effect on the enkephalin-degrading enzymes of human plasma]. AU - Zolotarev,Iu A, AU - Sokolov,O Iu, AU - Kost,N V, AU - Vas'kovskiĭ,B V, AU - Miasoedov,N F, AU - Zozulia,A A, PY - 2004/9/4/pubmed PY - 2005/2/24/medline PY - 2004/9/4/entrez SP - 234 EP - 40 JF - Bioorganicheskaia khimiia JO - Bioorg Khim VL - 30 IS - 3 N2 - A method of analysis of enkephalinase activity in blood plasma based on the application of Leu-enkephalin generally labeled with tritium at all its amino acid residues was developed. The method allows the simultaneous estimation of activity of several peptidases in microquantities of tissues. [G-3H]Leu-enkephalin was prepared by the method of solid phase catalytic isotope exchange (120 Ci/mmol) and subjected to proteolysis by the treatment with blood plasma. The resulting radioactive metabolites were separated by HPLC in the presence of the mixture of unlabeled fragments of Leu-enkephalin as internal standards. It was shown that aminopeptidases, dipeptidylaminopeptidases, and dipeptidylcarboxypeptidases respond for approximately 80%, 2%, and 10% of the total enzymatic activity, respectively. The new pathway of degradation of Leu-enkephalin by carboxypeptidase that provides for approximately 6% of the total enkephalin-degrading activity was discovered. Bestatin was shown to predominantly inhibit aminopeptidases and carboxypeptidases, whereas Selank is more specific for carboxypeptidases and dicarboxypeptidases. The English version of the paper: Russian Journal of Bioorganic Chemistry, 2004, vol. 30, no. 3; see also http://www.maik.ru. SN - 0132-3423 UR - https://www.unboundmedicine.com/medline/citation/15344652/[Leu_enkephalin_homogeneously_labeled_with_tritium_in_studying_the_Selank_inhibiting_effect_on_the_enkephalin_degrading_enzymes_of_human_plasma]_ DB - PRIME DP - Unbound Medicine ER -